Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) FCF Margin (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed FCF Margin for 14 consecutive years, with 19.0% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 1396.0% to 19.0% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 18.62% through Dec 2025, down 1043.0% year-over-year, with the annual reading at 18.62% for FY2025, 1043.0% down from the prior year.
  • FCF Margin hit 19.0% in Q4 2025 for Corcept Therapeutics, down from 26.24% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 50.5% in Q3 2021 to a low of 3.2% in Q1 2025.
  • Historically, FCF Margin has averaged 29.61% across 5 years, with a median of 32.11% in 2022.
  • Biggest five-year swings in FCF Margin: tumbled -3085bps in 2022 and later surged 2887bps in 2024.
  • Year by year, FCF Margin stood at 49.95% in 2021, then crashed by -35bps to 32.37% in 2022, then plummeted by -87bps to 4.08% in 2023, then skyrocketed by 707bps to 32.95% in 2024, then plummeted by -42bps to 19.0% in 2025.
  • Business Quant data shows FCF Margin for CORT at 19.0% in Q4 2025, 26.24% in Q3 2025, and 22.57% in Q2 2025.